Tetra Releases Full Results of FRAXA-Funded Clinical Trial of PDE4D Inhibitor

Tetra Releases Full Results of FRAXA-Funded Clinical Trial of PDE4D Inhibitor

Today, Tetra Therapeutics published the full results of its PDE4D trial published the full results to their announcement. Now having reviewed the full results, FRAXA can confidently say that the PDE4D drug trial gives hope to patients and families that Fragile X Syndrome is a treatable disorder, and this particular drug can improve intellectual disability.

Read more